Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 5:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 1,514 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Saline 0.9% Clear all
Suspended Phase 3 Interventional

Ketorolac Applied by Continuous IV Infusion for Treatment of Moderately Severe Postoperative Pain Following Bunionectomy

NCT05324358
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Ketorolac Tromethamine, Morphine Sulfate, Intravenous Placebo for NTM-001, IV Placebo for Morphine
Drug · Other
Lead sponsor
Neumentum, Inc.
Other
Eligibility
18 Years to 64 Years
Enrollment
341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
10
States / cities
Sun City, Arizona • Bakersfield, California • Canoga Park, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 24, 2026, 5:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Gut Butyrate and Blood Pressure in African Americans

NCT04415333
View directory record Official record
Conditions
Hypertension
Interventions
Sodium Butyrate 5 mmol, Sodium Butyrate 80 mmol
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
30 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Greensboro, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 18, 2023 · Synced Oct 24, 2026, 5:32 AM EDT
Terminated Phase 3 Interventional

Safety and Effectiveness of Visipaque 320mg-I/ml for Use in Contrast-Enhanced CT Angiography of Arteries of the Heart

NCT00335335
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
iodixanol
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 25, 2019 · Synced Oct 24, 2026, 5:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety of and Immune Response to HIV-MAG DNA Vaccine With or Without Plasmid IL-12 Adjuvant Delivered Intramuscularly Via Electroporation Followed by VSV-gag HIV Vaccine Boost in Healthy, HIV-Uninfected Adults

NCT01578889
View directory record Official record
Conditions
HIV Infections
Interventions
HIV-MAG vaccine, IL-12 pDNA adjuvant, VSV HIV gag vaccine, Placebo, Ichor Medical Systems TriGrid™ Delivery System (TDS) electroporation (EP) device
Biological · Device
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
5
States / cities
New York, New York • Rochester, New York • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Oct 24, 2026, 5:32 AM EDT
Withdrawn Phase 2Phase 3 Interventional

Hypertonic Versus Isotonic Saline Irrigations for Chronic Rhinosinusitis

NCT04242368
View directory record Official record
Conditions
Chronic Rhinosinusitis (Diagnosis)
Interventions
Isotonic saline, Hypertonic Nasal Wash, Fluticasone Propionate
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 18, 2021 · Synced Oct 24, 2026, 5:32 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study Combining Bortezomib With High Dose Melphalan to Treat Multiple Myeloma

NCT00784823
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Bortezomib 1 mg/m2, Bortezomib 1.3 mg/m2, Bortezomib 1.6 mg/m2, Melphalan
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years to 76 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 11, 2022 · Synced Oct 24, 2026, 5:32 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Comparing Intra-articular Corticosteroid to Intra-articular Ketorolac Knee Injections

NCT02612272
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Ketorolac, Betamethasone
Drug
Lead sponsor
St. Luke's Hospital, Pennsylvania
Other
Eligibility
18 Years and older · Male only
Enrollment
448 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Bethlehem, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 13, 2016 · Synced Oct 24, 2026, 5:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety and Immunogenicity Study of Heterologous and Homologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants

NCT02325050
View directory record Official record
Conditions
Healthy
Interventions
MVA-BN-Filo, Ad26. ZEBOV, Placebo
Biological · Other
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 50 Years
Enrollment
164 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 24, 2026, 5:32 AM EDT
Not yet recruiting Early Phase 1 Interventional

Coupled Gentamicin-Lactobacillus Rhamnosus in NLUTD

NCT07643974
View directory record Official record
Conditions
Spinal Cord Injury, Neurogenic Bladder (NB), Neurogenic Lower Urinary Tract Dysfunction, Multiple Sclerosis, Spina Bifida, Urinary Tract Infection(UTI)
Interventions
Gentamicin, Lactobacillus Rhamnosus GG
Drug
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 24, 2026, 5:32 AM EDT
Recruiting No phase listed Observational

Neuroimaging in Healthy Aging and Senile Dementia (HASD_IND)

NCT04579120
View directory record Official record
Conditions
Alzheimer Disease
Interventions
[11C]-Pittsburgh Compound B ([11C]PiB), F 18 AV-1451 (Flortaucipir)
Drug
Lead sponsor
Tammie L. S. Benzinger, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 24, 2026, 5:32 AM EDT
Completed Phase 1 Interventional

PM14 Administered Intravenously to Patients With Advanced Solid Tumors

NCT05076396
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
PM14
Drug
Lead sponsor
PharmaMar
Industry
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 24, 2026, 5:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety and Immunogenicity Study of Intranasal Sendai Virus Vectored Respiratory Syncytial Virus (SeVRSV) Vaccine in Healthy Adults

NCT03473002
View directory record Official record
Conditions
Antiviral Prophylaxis, Respiratory Syncytial Virus Infection
Interventions
Placebo, SeVRSV Vaccine
Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 1, 2019 · Synced Oct 24, 2026, 5:32 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Ketorolac Use in Pediatric Patients Undergoing Tonsillectomy

NCT03453541
View directory record Official record
Conditions
Analgesic Adverse Reaction
Interventions
Ketorolac Tromethamine, 0.9% Normal Saline
Drug
Lead sponsor
Albany Medical College
Other
Eligibility
2 Years to 18 Years
Enrollment
214 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 24, 2026, 5:32 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Intranasal Lidocaine for Prevention of Postoperative Nausea and Vomiting.

NCT04810494
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
2% Lidocaine HCl topical solution, 0.9% Sodium chloride
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 12, 2022 · Synced Oct 24, 2026, 5:32 AM EDT
Completed Phase 1 Interventional

A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies

NCT02740985
View directory record Official record
Conditions
Advanced Solid Malignancies, Non-Small Cell Lung Cancer (NSCLC), Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC), Colorectal Carcinoma (CRC)
Interventions
AZD4635, Durvalumab, Abiraterone Acetate, Enzalutamide, Oleclumab, Docetaxel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
17
States / cities
Fayetteville, Arkansas • Fresno, California • Denver, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated May 26, 2023 · Synced Oct 24, 2026, 5:32 AM EDT
Completed Phase 2 Interventional Results available

Zoledronic Acid in Preventing Osteoporosis in Patients Undergoing Donor Stem Cell Transplant

NCT00321932
View directory record Official record
Conditions
Leukemia, Lymphoma, Myelodysplastic Syndromes, Osteoporosis, Ovarian Cancer
Interventions
calcium, cholecalciferol, zoledronic acid
Dietary Supplement · Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
2
States / cities
Minneapolis, Minnesota • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Oct 24, 2026, 5:32 AM EDT
Terminated Phase 2 Interventional

A Randomized, Double-Blind, Placebo Controlled, Multicenter, Efficacy and Safety Trial of Single Cycle Tetrodotoxin in the Treatment of Chemotherapy Induced Neuropathic Pain

NCT05359133
View directory record Official record
Conditions
Chemotherapy-induced Neuropathic Pain, Chemotherapy-induced Peripheral Neuropathy
Interventions
Tetrodotoxin, Placebo
Drug
Lead sponsor
Wex Pharmaceuticals Inc.
Industry
Eligibility
21 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
15
States / cities
Santa Ana, California • Santa Rosa, California • Port Charlotte, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Oct 24, 2026, 5:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Comparing Organic Phosphate (Sodium Glycerophosphate Injection) to Numeta G16%E

NCT06842134
View directory record Official record
Conditions
Parenteral Nutrition
Interventions
Numeta G16%E, Sodium Glycerophosphate Injection
Drug
Lead sponsor
Baxter Healthcare Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 29, 2025 · Synced Oct 24, 2026, 5:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Immunogenicity, and Dose Ranging Study of Inactivated Zika Virus Vaccine in Healthy Participants

NCT03343626
View directory record Official record
Conditions
Virus, Zika, Zika Virus Disease, Flavivirus Infections, Healthy Participants
Interventions
Placebo, PIZV
Drug · Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 49 Years
Enrollment
271 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
7
States / cities
Coral Gables, Florida • Miami, Florida • Lenexa, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2022 · Synced Oct 24, 2026, 5:32 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Analgesic Efficacy of Interscalene Nerve Block Versus Local Infiltration Analgesia Following Total Shoulder Arthroplasty

NCT02876055
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Single shot interscalene nerve block, Continuous interscalene nerve block, Local Infiltration Analgesia (LIA)
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 24, 2026, 5:32 AM EDT
Completed Phase 2 Interventional Results available

Fluid Chloride and AKI in Cardiopulmonary Bypass

NCT02668952
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
0.9% Normal Saline (0.9% Sodium Chloride) injection, Isolyte S injection
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Oct 24, 2026, 5:32 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Assess the Safety, Pharmacokinetics/Dynamics of DS-1040b in Subjects With Acute Submassive Pulmonary Embolism

NCT02923115
View directory record Official record
Conditions
Pulmonary Embolism, Thrombotic Disease
Interventions
DS-1040b, Placebo, Enoxaparin
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 75 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
15
States / cities
Mobile, Alabama • Beverly Hills, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2023 · Synced Oct 24, 2026, 5:32 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older

NCT04537208
View directory record Official record
Conditions
COVID-19 (Healthy Volunteers)
Interventions
CoV2 preS dTM-AF03 (low-dose), CoV2 preS dTM-AF03 (high-dose), CoV2 preS dTM-AS03 (low-dose), CoV2 preS dTM-AS03 (high-dose), CoV2 preS dTM (high-dose) without adjuvant, Placebo (0.9% normal saline)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
441 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
11
States / cities
Birmingham, Alabama • Rolling Hills Estates, California • Hollywood, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 24, 2026, 5:32 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Subcutaneous Bupivacaine Decrease Post-op Pain in Patients Undergoing C-Section

NCT03383588
View directory record Official record
Conditions
Pain, Referred
Interventions
Bupivacaine, Morphine, Fentanyl, Epinephrine, Saline solution
Drug · Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
17 Years to 40 Years · Female only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 24, 2026, 5:32 AM EDT